Applied Clinical Trials
Survey data finds that physicians aren’t very familiar with the intricacies of nucleic acid-based therapies.
Meghan Oates-Zalesky
Despite the buzz, physicians have limited familiarity and understanding with the burgeoning category of nucleic acid-based therapies. New data sourced in September 2019 by InCrowd, a real-time market insights technology firm, provides a baseline on physicians’ current knowledge regarding the different types of therapies, their mechanisms of action, and their perceived current impact and future promise. Based on responses, the market shows significant knowledge gaps.
Only 56% of screened respondents report being at least somewhat familiar with the seven leading nucleic acid-based therapies today-RNAi, siRNA, ASO, mRNA, AAV, CRISPR, and TALENs. Only 28% of physicians surveyed considered themselves familiar or very familiar with these therapies, and only 7% reported high familiarity.
Oncologists have the highest familiarity of the specialists surveyed, at 52% (compared to 20% of PCPs and 15% of pediatricians). Physicians in academic settings noted greater familiarity (34%) than physicians in non-academic community practices (24%).
The terms mRNA and CRISPR are the most familiar, at 92% and 64%, respectively, for familiarity. Less than half of respondents were familiar with AAV (44%), siRNA (39%), RNAi (38%), and ASO (36%)-and less than a fifth (19%) with TALENS. Again, oncologists had the highest familiarity across terms compared to PCPs and pediatricians.
Academic-based physicians reported higher levels of awareness on many terms. For example, 70% of academic practice-based respondents are familiar with CRISPR versus 58% in non-academic settings.
There was a lack of knowledge around which among the list was a gene therapy. CRISPR, TALENS, and AAV are most commonly considered “gene therapies” by respondents, at 92%, 72%, and 67% respectively. About half associate the term with other therapies including RNAi (54%), siRNA (53%), ASO (51%), and mRNA (48%).
CRISPR also led the ranking for promising treatments, at 27% among all respondents, and 44% among oncologists. mRNA ranked second, at 8% of respondents. Practice setting-academic vs. community-based-did not impact results.
Beyond basic uses
Understanding basic uses for nucleic acid-based therapies-like the use of CRISPR for permanent DNA edits, and the use of mRNA and AAV for the creation of vaccine vectors-varied between one-third to two-thirds of respondents. Significant confusion existed on:
The findings suggest biotechs and pharma firms face an opportunity for physician outreach and education on gene-based therapy fundamentals, as well as initiatives that build awareness of approved therapies and progress of others through the pipeline.
The survey included a total of 250 clinicians, including PCPs (48%), oncologists (32%), and pediatricians (20%), with a near equal split between those academically associated (47%) and non-associated (53%) practices. Each respondent needed to have at least a limited familiarity with RNA- or DNA-based therapeutic methods at a minimum to complete the survey.
Meghan Oates-Zalesky, Senior VP of Marketing, InCrowd
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.